Temasek Holdings’s Coherus Oncology CHRS Stock Holding History

Temasek Holdings’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,818,802	Closed	-$10.1M	–	125
2024 Q2	$10.1M	Sell	5,818,802 -1,562,314	-21%	-$3.14M	0.05%	77
2024 Q1	$17.6M	Hold	7,381,116	–	–	0.1%	59
2023 Q4	$24.6M	Hold	7,381,116	–	–	0.14%	48
2023 Q3	$27.6M	Hold	7,381,116	–	–	0.16%	46
2023 Q2	$31.5M	Hold	7,381,116	–	–	0.18%	42
2023 Q1	$50.5M	Hold	7,381,116	–	–	0.3%	39
2022 Q4	$58.5M	Hold	7,381,116	–	–	0.34%	39
2022 Q3	$70.9M	Hold	7,381,116	–	–	0.42%	39
2022 Q2	$53.4M	Hold	7,381,116	–	–	0.29%	43
2022 Q1	$95.3M	Hold	7,381,116	–	–	0.4%	41
2021 Q4	$118M	Hold	7,381,116	–	–	0.43%	44
2021 Q3	$119M	Hold	7,381,116	–	–	0.42%	45
2021 Q2	$102M	Hold	7,381,116	–	–	0.34%	40
2021 Q1	$108M	Hold	7,381,116	–	–	0.42%	37
2020 Q4	$128M	Hold	7,381,116	–	–	0.55%	31
2020 Q3	$135M	Hold	7,381,116	–	–	0.69%	26
2020 Q2	$132M	Hold	7,381,116	–	–	0.79%	20
2020 Q1	$120M	Hold	7,381,116	–	–	0.88%	19
2019 Q4	$133M	Buy	7,381,116 +825,000	+13%	+$15.2M	0.87%	19
2019 Q3	$133M	Hold	6,556,116	–	–	0.97%	21
2019 Q2	$145M	Hold	6,556,116	–	–	1.04%	19
2019 Q1	$89.4M	Hold	6,556,116	–	–	0.62%	28
2018 Q4	$59.3M	Hold	6,556,116	–	–	0.41%	37
2018 Q3	$108M	Hold	6,556,116	–	–	0.63%	33
2018 Q2	$91.8M	Hold	6,556,116	–	–	0.48%	35
2018 Q1	$72.4M	Hold	6,556,116	–	–	0.4%	35
2017 Q4	$57.7M	Hold	6,556,116	–	–	0.35%	36
2017 Q3	$87.5M	Buy	+6,556,116	New	+$86.7M	0.51%	25

Other funds holding CHRS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings's CHRS Position: Q3 2024 in Review

Temasek Holdings sold out of Coherus Oncology (CHRS) in Q3 2024, closing a stake of 5,818,802 shares — an estimated $10.1M sold.

Temasek Holdings first reported a position in CHRS in Q3 2017 and held it in 28 quarters. The position peaked at $145M in Q2 2019. 128 funds tracked by Wall St. Rank hold CHRS as of Q3 2024.

Temasek Holdings reported no remaining Coherus Oncology position as of Q3 2024 after selling out during the quarter.
Temasek Holdings sold 5,818,802 Coherus Oncology shares in Q3 2024, an estimated $10.1M.
Temasek Holdings first reported a position in Coherus Oncology in Q3 2017 and held it in 28 quarters.
Temasek Holdings's Coherus Oncology position peaked at $145M in Q2 2019.
128 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2024.

Based on Temasek Holdings's 13F filing for Q3 2024, filed 14 Nov 2024.